Elanco Animal Health Inc (Form: 8-K, Received: 12/20/2019 16:32:34)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 20, 2019

Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

Indiana

001-38661

82-5497352

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

2500 Innovation Way

Greenfield, Indiana

(Address of principal executive offices)

46140

(Zip Code)

Registrant’s telephone number, including area code: (877) 352-6261

Not Applicable

(Former Name or Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, no par value	ELAN	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement.

On December 20, 2019, Elanco Animal Health Incorporated (the “Company”) entered into a First Amendment to the Revolving Loan Credit Agreement, dated as of September 5, 2018, among the Company, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders parties thereto (the “Revolving Loan Amendment”), and a First Amendment to the Term Loan Credit Agreement, dated as of September 5, 2018, among the Company, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders parties thereto (the “Term Loan Amendment” and, together with the Revolving Loan Amendment, the “Amendments”). The Amendments permit the Company to create, assume or suffer to exist liens on any amounts held by a trustee under any indenture or other debt agreement issued in escrow pursuant to customary escrow arrangements pending the release thereof, or under any indenture or other debt agreement pursuant to customary discharge, redemption or defeasance provisions, as well as to incur any related indebtedness.

The foregoing descriptions of the Revolving Loan Amendment and the Term Loan Amendment are qualified in their entirety by reference to the Revolving Loan Amendment and the Term Loan Amendment, which are filed as Exhibits 10.1 and 10.2, respectively, hereto, and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
10.1		First Amendment to Revolving Loan Credit Agreement, dated as of September 5, 2018, among Elanco Animal Health Incorporated, as borrower, JPMorgan Chase Bank, N.A., as administrative agent and the other Lenders party thereto.
10.2		First Amendment to Term Loan Credit Agreement, dated as of September 5, 2018, among Elanco Animal Health Incorporated, as borrower, JPMorgan Chase Bank, N.A., as administrative agent and the other Lenders party thereto.
104.1		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Elanco Animal Health Incorporated

Date: December 20, 2019	By:	/s/ Michael Bryant-Hicks
		Name: Michael-Bryant Hicks
		Title: Executive Vice President, General Counsel and Corporate Secretary

Exhibit 10.1

Execution Version

FIRST AMENDMENT TO REVOLVING LOAN CREDIT AGREEMENT

THIS FIRST AMENDMENT TO REVOLVING LOAN CREDIT AGREEMENT, dated as of December 20, 2019 (this “Amendment”), to the Credit Agreement referenced below is by and among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the “Borrower”), the Lenders identified on the signature pages hereto and JPMORGAN CHASE BANK, N.A., in its capacity as administrative agent for the Lenders (in such capacity, the “Administrative Agent”).

W I T N E S S E T H

WHEREAS, a revolving credit facility has been extended to the Borrower pursuant to the Revolving Loan Credit Agreement (as further amended, modified, supplemented, increased and extended from time to time, the “Credit Agreement”) dated as of September 5, 2018, among the Borrower, the Lenders party thereto and the Administrative Agent; and

WHEREAS, the parties hereto desire to amend the Credit Agreement on the terms set forth herein;

NOW, THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

Section 1. Defined Terms. Capitalized terms used herein but not otherwise defined herein shall have the meanings provided to such terms in the Credit Agreement.

Section 2. Amendments.

(a) Section 1.01 of the Credit Agreement is hereby amended by inserting in such Section the following definitions in the appropriate alphabetical order:

“Escrow Securities” means any Debt of the Borrower or any Subsidiary secured by a Lien described under Section 8.02(s).

(b) The definition of “Consolidated Interest Charges” in Section 1.01 of the Credit Agreement is hereby amended by adding the clause “; provided, further, that there shall be excluded from Consolidated Interest Charges any interest, premium payments, debt discount, fees, charges and related expenses in connection with any Escrow Securities” after “4/3” and before the “.” of the definition.

(c) The definition of “Consolidated Total Debt” in Section 1.01 of the Credit Agreement is hereby amended by adding the clause “; provided that there shall be excluded from Consolidated Total Debt the proceeds of any Escrow Securities” after “Liens” and before the “.” of the definition.

(d) The definition of “Permitted Debt” in Section 1.01 of the Credit Agreement is hereby amended by (i) adding the clause “, (viii) Debt with respect to any Escrow Securities and any Guarantee thereof and (ix)” after “funds” and before the “and (viii)” of the definition and (ii) deleting “and (viii)”.

(e) Section 8.02 of the Credit Agreement is hereby amended by deleting the last “and” in clause (q) and adding an “and” at the end of clause (r).

(f) A new Section 8.02(s) is added to the end of Section 8.02 of the Credit Agreement to read as follows:

(s) Liens on any amounts held by a trustee under any indenture or other debt agreement issued in escrow pursuant to customary escrow arrangements pending the release thereof, or under any indenture or other debt agreement pursuant to customary discharge, redemption or defeasance provisions.

(g) Section 8.05 of the Credit Agreement is hereby adding “and Section 8.02(s)” at the end of the first parenthetical.

Section 3. Conditions Precedent. The amendments set forth in Section 2 of this Amendment shall only become effective on the date (the “First Amendment Effective Date”) when each of the following conditions have been satisfied (or waived) in accordance with the terms therein:

(a) receipt by the Administrative Agent (or its counsel) from each party hereto either (i) a counterpart of this Amendment signed on behalf of such party or (ii) written evidence satisfactory to the Administrative Agent (which may include telecopy transmission or other electronic communication) of a signed signature page of this Amendment) that such party has signed a counterpart of this Amendment; and

(b) the Borrower shall have paid (or caused to be paid) all reasonable and documented accrued fees and expenses of the Administrative Agent (including the reasonable and documented fees and expenses of counsel to the Administrative Agent).

Section 4. Amendment is a “Loan Document”. This Amendment is a Loan Document and all references to a “Loan Document” in the Credit Agreement and the other Loan Documents (including, without limitation, all such references in the representations and warranties in the Credit Agreement and the other Loan Documents) shall be deemed to include this Amendment.

Section 5. Reaffirmation of Representations and Warranties; No Default. The Borrower represents and warrants to the Administrative Agent and each Lender that, immediately after giving effect to this Amendment, (a) the representations and warranties of the Borrower contained in Article V of the Credit Agreement or in any other Loan Document, or which are contained in any document furnished at any time under or in connection with the Credit Agreement or any other Loan Document, are true and correct in all material respects (or, to the extent such representation or warranty is qualified by materiality or Material Adverse Effect, it shall be true and correct in all respects as drafted) on and as of the First Amendment Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (or, if such representation or warranty is qualified by materiality or Material Adverse Effect, it shall be true and correct in all respects as drafted) as of such earlier date and (b) no Default exists.

Section 6. Reaffirmation of Obligations. The Borrower (a) acknowledges and consents to all of the terms and conditions of this Amendment, (b) affirms all of its obligations under the Loan Documents and (c) agrees that this Amendment and all documents executed in connection herewith do not operate to reduce or discharge the Borrower’s obligations under the Loan Documents.

Section 7. No Other Changes. Except as modified hereby, all of the terms and provisions of the Loan Documents shall remain in full force and effect.

Section 8. Counterparts; Delivery. This Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of this Amendment by facsimile or other electronic imaging means shall be effective as an original. This Amendment shall be effective upon receipt by the Administrative Agent of counterparts of this Amendment, duly executed by an officer of the Borrower and by the Required Lenders.

Section 9. Governing Law. This Amendment shall be deemed to be a contract made under, and for all purposes shall be construed in accordance with, the laws of the State of New York.

[Signatures begin on the following page]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date first above written.

ELANCO ANIMAL HEALTH INCORPORATED, a Delaware limited liability company, as Borrower


By:	/s/ Jeffrey N. Simmons
	Name:	Jeffrey N. Simmons
	Title:	President and Chief Executive Officer

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

JPMORGAN CHASE BANK, N.A.,
as Administrative Agent


By:	/s/ Joseph McShane
	Name:	Joseph McShane
	Title:	Vice President


JPMORGAN CHASE BANK, N.A., as Lender


By:	/s/ Joseph McShane
	Name:	Joseph McShane
	Title:	Vice President

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Lender


By:	/s/ Judy Smith
	Name:	Judy Smith
	Title:	Authorized Signatory


By:	/s/ Lingzi Huang
	Name:	Lingzi Huang
	Title:	Authorized Signatory

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

DEUTSCHE BANK AG NEW YORK BRANCH, as Lender


By:	/s/ Ming K. Chu
	Name:	Ming K. Chu
	Title:	Director


By:	/s/ Virginia Cosenza
	Name:	Victoria Cosenza
	Title:	Vice President

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

BNP PARIBAS, as Lender


By:	/s/ Michael Pearce
	Name:	Michael Pearce
	Title:	Managing Director


By:	/s/ John Bosco
	Name:	John Bosco
	Title:	Managing Director

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

BARCLAYS BANK PLC, as Lender


By:	/s/ Edward Pan
	Name:	Edward Pan
	Title:	Associate

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

Citibank N.A., as Lender


By:	/s/ Patricia A. Guerra
	Name:	Patricia A. Guerra
	Title:	Vice President

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

Morgan Stanley Bank, N.A., as Lender


By:	/s/ Jackson Eng
	Name:	Jackson Eng
	Title:	Authorized Signatory

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

BANK OF AMERICA, N.A., as Lender


By:	/s/ Darren Merten
	Name:	Darren Merten
	Title:	Vice President

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

GOLDMAN SACHS BANK USA, as Lender


By:	/s/ Jamie Minieri
	Name:	Jamie Minieri
	Title:	Authorized Signatory

[Signature Page to First Amendment to Revolving Loan Credit Agreement]

Exhibit 10.2

Execution Version

FIRST AMENDMENT TO TERM LOAN CREDIT AGREEMENT

THIS FIRST AMENDMENT TO TERM LOAN CREDIT AGREEMENT, dated as of December 20, 2019 (this “Amendment”), to the Credit Agreement referenced below is by and among ELANCO ANIMAL HEALTH INCORPORATED, an Indiana corporation (the “Borrower”), the Lenders identified on the signature pages hereto and JPMORGAN CHASE BANK, N.A., in its capacity as administrative agent for the Lenders (in such capacity, the “Administrative Agent”).

W I T N E S S E T H

WHEREAS, credit has been extended to the Borrower pursuant to the Term Loan Credit Agreement (as further amended, modified, supplemented, increased and extended from time to time, the “Credit Agreement”) dated as of September 5, 2018, among the Borrower, the Lenders party thereto and the Administrative Agent; and

WHEREAS, the parties hereto desire to amend the Credit Agreement on the terms set forth herein;

NOW, THEREFORE, in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

Section 1. Defined Terms. Capitalized terms used herein but not otherwise defined herein shall have the meanings provided to such terms in the Credit Agreement.

Section 2. Amendments.

(a) Section 1.01 of the Credit Agreement is hereby amended by inserting in such Section the following definitions in the appropriate alphabetical order:

“Escrow Securities” means any Debt of the Borrower or any Subsidiary secured by a Lien described under Section 8.02(s).

(e) Section 8.02 of the Credit Agreement is hereby amended by deleting the last “and” in clause (q) and adding an “and” at the end of clause (r).

(f) A new Section 8.02(s) is added to the end of Section 8.02 of the Credit Agreement to read as follows:

(g) Section 8.05 of the Credit Agreement is hereby adding “and Section 8.02(s)” at the end of the first parenthetical.

Section 7. No Other Changes. Except as modified hereby, all of the terms and provisions of the Loan Documents shall remain in full force and effect.

Section 9. Governing Law. This Amendment shall be deemed to be a contract made under, and for all purposes shall be construed in accordance with, the laws of the State of New York.

[Signatures begin on the following page]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date first above written.

ELANCO ANIMAL HEALTH INCORPORATED, a Delaware limited liability company, as Borrower


By:	/s/ Jeffrey N. Simmons
	Name:	Jeffrey N. Simmons
	Title:	President and Chief Executive Officer